Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Outlook's eye disease drug fails to match Lucentis, sinking stock
The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback.
Nick Paul Taylor
Nov 27, 2024 8:40am
PTC axes utreloxastat program after phase 2 ALS failure
Nov 27, 2024 4:45am
Amgen obesity drug matches competition but investors unimpressed
Nov 26, 2024 10:11am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
Roche's TIGIT prospect fails another phase 3 lung cancer test
Nov 26, 2024 4:11am
Biohaven fails phase 3 SMA test but plans talks with FDA
Nov 25, 2024 9:56am
